^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Breast Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor) +
    PLX038 (Topoisomerase I inhibitor, DDR enhancer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Mol Cancer Ther
    Title:

    PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors

    Published date:
    11/03/2022
    Excerpt:
    PLX038 monotherapy and combination with PARP inhibition potently inhibited the growth of both BRCA1- and ATM-deficient tumors. A patient with an ATM-mutated breast cancer treated with PLX038 and the PARP inhibitor rucaparib achieved rapid, symptomatic, and radiographic complete response lasting 12 months.
    DOI:
    10.1158/1535-7163.MCT-22-0217
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Mol Cancer Ther
    Title:

    PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors

    Published date:
    08/23/2022
    Excerpt:
    A patient with an ATM mutated breast cancer treated with PLX038 and the PARP inhibitor rucaparib achieved rapid, symptomatic, and radiographic complete response lasting twelve months. Single agent PLX038 or PLX038 in combination with DNA damage response inhibitors are novel therapeutic paradigms for patients with ATM-loss cancers.
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-22-0217